Home > Oncology > ASCO 2021 > Basic Science > PARP7 inhibitor shows promising results in first-in-human trial

PARP7 inhibitor shows promising results in first-in-human trial

Presented By
Dr Gerald Falchook , Sarah Cannon Research Institute at HealthONE, CO, USA
Conference
ASCO 2021
Trial
Phase 1
RBN-2397 is a potent, selective inhibitor of PARP7 that could potentially release the brake on the anti-tumour immunity. It was well tolerated and demonstrated proof of mechanism in a first-in-human trial. Targeting cytosolic nucleic acid sensing pathways and the Type I interferon response is an emerging therapeutic strategy in oncology. PARP7 is a member of the poly-ADP-ribose polymerases (PARP) enzymes and acts as a brake on the cellular stress response by negatively regulating the Type I interferon response. PARP7 expressed in cancer cells blocks anti-tumour immunity and is, therefore, a potential novel therapeutic target. RBN-2397 is a potent, selective inhibitor of PARP7 that could potentially release the brake on the anti-tumour immunity. In preclinical models, RBN-2397 restored Type I interferon signalling in tumours, caused complete tumour regressions, and induced adaptive immunity [1]. Dr Gerald Falchook (Sarah Cannon Research Institute at ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on